Consensus CSPC Pharmaceutical Group Limited

Stocks

1093

HK1093012172

Pharmaceuticals

Market Closed - Hong Kong S.E. 01:38:03 04/09/2026 pm IST			5-day change	1st Jan Change
9.685 ^HKD	+0.78%		+1.63%	+14.89%

01/09	CSPC Pharma's Cancer Drug Gets Breakthrough Therapy Designation for New Indication in China	MT
01/09	CSPC Pharma's SYS6010 Gets Breakthrough Therapy Designation for New Indication in China	MT

Evolution of the Average Target: CSPC Pharmaceutical Group Limited

Evolution of the Target Price: CSPC Pharmaceutical Group Limited

Changes in Analyst Recommendations: CSPC Pharmaceutical Group Limited

642a7e.BUOJcXHiH8w7JjFP_4JRTXIA3iOrAd1bfeiT-JPwkoM.Rxr7QDeIKrlfYEsstrcBFRdYj3Tnc-8WL6Dcrtq95c9rLMJHLq99tU9OaA~e969f9ad866d9ff0f2f9e8bc1b169ac1

Analysts' recommendations: CSPC Pharmaceutical Group Limited

24/08	Nomura Adjusts CSPC Pharmaceutical Group's Price Target to HK$10.93 From HK$10.31, Keeps at Buy	MT
21/08	UOB Kay Hian Upgrades CSPC Pharmaceutical Group to Buy from Sell; Price Target is HK$11.50	MT
27/07	Nomura Adjusts CSPC Pharmaceutical Group's Price Target to HK$10.31 From HK$12.04, Keeps at Buy	MT
28/05	UOB Kay Hian Downgrades CSPC Pharmaceutical Group to Sell from Hold; Price Target is HK$6	MT
26/03	Jefferies Adjusts CSPC Pharmaceutical Group's Price Target to HK$7.20 From HK$5.90, Keeps at Underperform	MT
16/02	Nomura Adjusts CSPC Pharmaceutical Group's Price Target to HK$12.04 From HK$9.11, Keeps at Buy	MT
21/11	UOB Kay Hian Downgrades CSPC Pharmaceutical Group to Hold from Buy; Price Target is HK$8.50	MT
21/11	Nomura Adjusts CSPC Pharmaceutical Group's Price Target to HK$9.11 from HK$10.09, Keeps at Buy	MT
20/25/20	CSPC Pharmaceutical says JSKN003 granted breakthrough therapy designation in China	RE
13/25/13	CSPC Pharmaceutical announces NMPA acceptance of new drug application for Efmedaglutide Alfa Injection	RE
09/25/09	CSPC Pharmaceutical's Hypertriglyceridemia Drug Secures FDA Nod for US Trial	MT
25/25/25	Jefferies Adjusts CSPC Pharmaceutical Group's Price Target to HK$5.90 From HK$5, Keeps at Underperform	MT
17/25/17	Nomura Adjusts CSPC Pharmaceutical Group's Price Target to HK$10.09 From HK$10.22, Keeps at Buy	MT
16/25/16	Macquarie Upgrades CSPC Pharmaceutical Group to Outperform from Neutral; Price Target is HK$10.30	MT
16/25/16	Nomura Adjusts CSPC Pharmaceutical Group's Price Target to HK$10.22 From HK$8.02, Keeps at Buy	MT
29/25/29	Nomura Adjusts CSPC Pharmaceutical Group's Price Target to HK$8.02 From HK$6.55, Keeps at Buy	MT
31/25/31	Nomura Adjusts CSPC Pharmaceutical Group's Price Target to HK$6.55 From HK$6.48, Keeps at Buy	MT
26/25/26	Nomura Adjusts CSPC Pharmaceutical Group's Price Target to HK$6.48 From HK$7.02, Keeps at Buy	MT
18/24/18	Nomura Adjusts CSPC Pharmaceutical Group's Price Target to HK$7.02 From HK$8.46, Keeps at Buy	MT
22/24/22	Nomura Adjusts CSPC Pharmaceutical Group's Price Target to HK$8.46 From HK$9.29, Keeps at Buy	MT
23/24/23	Zhongtai International Downgrades CSPC Pharmaceutical to Neutral From Buy; Price Target is HK$6.10	MT
22/24/22	Nomura Adjusts CSPC Pharmaceutical's Price Target to HK$9.29 From HK$9.83, Keeps at Buy	MT
22/24/22	Daiwa Securities Downgrades CSPC Pharmaceutical to Neutral From Outperform; Price Target is HK$6	MT
22/24/22	UOB Kay Hian Downgrades CSPC Pharmaceutical to Sell From Buy; Price Target is HK$5	MT
22/24/22	Bank of China International Downgrades CSPC Pharmaceutical to Hold From Buy; Price Target is HK$6.50	MT

More recommendations

Other Pharmaceuticals

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	CSPC PHARMACEUTICAL GROUP LIMITED					+28.41%
	ELI LILLY AND COMPANY					+14.46%
	JOHNSON & JOHNSON					+0.15%
	ABBVIE INC.					+7.85%
	ROCHE HOLDING AG					+3.73%
	NOVARTIS AG					-3.15%
	ASTRAZENECA PLC					+31.21%
	AMGEN INC.					-10.87%
	NOVO NORDISK A/S					+3.62%
	GILEAD SCIENCES, INC.					+4.25%
	Average					+7.96%
	Weighted average by Cap.					+7.06%